Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12995
mi
from
Saint Petersburg, FL
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12995
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 70
mi
from
Sunrise, FL
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 70
mi
from
Sunrise, FL
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Tampa, FL
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1367
mi
from
Chicago, IL
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1367
mi
from
Chicago, IL
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10345
mi
from
Evanston, IL
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10345
mi
from
Evanston, IL
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1303
mi
from
Northbrook, IL
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1303
mi
from
Northbrook, IL
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1334
mi
from
Lenexa, KA
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1334
mi
from
Lenexa, KA
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10346
mi
from
Advance, NC
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10346
mi
from
Advance, NC
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Columbus, OH
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10340
mi
from
Hershey, PA
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10340
mi
from
Hershey, PA
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10183
mi
from
Philadelphia, PA
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10183
mi
from
Philadelphia, PA
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10206
mi
from
Cordova, TN
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10206
mi
from
Cordova, TN
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1310
mi
from
Nashville, TN
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1310
mi
from
Nashville, TN
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1343
mi
from
Salt Lake City, UT
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1343
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 33013
mi
from
Innsbruck,
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 33013
mi
from
Innsbruck,
Click here to add this to my saved trials
Power Over Pain (POP) Study
Psychological Treatment of Disability-Related Pain: Efficacy and Mechanisms
Status: Enrolling
Updated:  12/31/1969
University of Washington, Ninth and Jefferson Building
mi
from
Seattle, WA
Power Over Pain (POP) Study
Psychological Treatment of Disability-Related Pain: Efficacy and Mechanisms
Status: Enrolling
Updated: 12/31/1969
University of Washington, Ninth and Jefferson Building
mi
from
Seattle, WA
Click here to add this to my saved trials
Applying Speed of Processing Training to Individuals With Multiple Sclerosis
Applying Speed of Processing Training (SPT) to Individuals With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Kessler Foundation
mi
from
West Orange, NJ
Applying Speed of Processing Training to Individuals With Multiple Sclerosis
Applying Speed of Processing Training (SPT) to Individuals With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Kessler Foundation
mi
from
West Orange, NJ
Click here to add this to my saved trials
Natural History of Optic Neuritis
Natural History of Optic Neuritis
Status: Enrolling
Updated:  12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Natural History of Optic Neuritis
Natural History of Optic Neuritis
Status: Enrolling
Updated: 12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Natural History of Optic Neuritis
Natural History of Optic Neuritis
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Natural History of Optic Neuritis
Natural History of Optic Neuritis
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Natural History of Optic Neuritis
Natural History of Optic Neuritis
Status: Enrolling
Updated:  12/31/1969
Hadassah Hospital/Hebrew University Medical Center
mi
from
Jerusalem,
Natural History of Optic Neuritis
Natural History of Optic Neuritis
Status: Enrolling
Updated: 12/31/1969
Hadassah Hospital/Hebrew University Medical Center
mi
from
Jerusalem,
Click here to add this to my saved trials
Idebenone for Primary Progressive Multiple Sclerosis
Open Label Extension Trial of Idebenone for Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Idebenone for Primary Progressive Multiple Sclerosis
Open Label Extension Trial of Idebenone for Primary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Francisco, CA
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Miami, FL
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Orlando, FL
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Tallahassee, FL
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Boston, MA
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Boston, MA
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Detroit, MI
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
New Brunswick, NJ
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Philadelphia, PA
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Salt Lake City, UT
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Parkville,
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Parkville,
Click here to add this to my saved trials
Wahls Paleo Diet and Progressive Multiple Sclerosis
Wahls Paleo Diet and Progressive Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Univeristy of Iowa
mi
from
Iowa City, IA
Wahls Paleo Diet and Progressive Multiple Sclerosis
Wahls Paleo Diet and Progressive Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Univeristy of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Walking While Talking: The Effect of Doing Two Things at Once in Individuals With Neurological Injury or Disease
Walking While Talking: The Effects of Dual Task on Gait and Cognition in Individuals With Neurological Injury or Disease.
Status: Enrolling
Updated:  12/31/1969
Stony Brook University RRAMP Laboratory
mi
from
Stony Brook, NY
Walking While Talking: The Effect of Doing Two Things at Once in Individuals With Neurological Injury or Disease
Walking While Talking: The Effects of Dual Task on Gait and Cognition in Individuals With Neurological Injury or Disease.
Status: Enrolling
Updated: 12/31/1969
Stony Brook University RRAMP Laboratory
mi
from
Stony Brook, NY
Click here to add this to my saved trials
A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis
A Randomized Trial of a Formal Group Program for Fatigue in Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis
A Randomized Trial of a Formal Group Program for Fatigue in Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis
A Randomized Trial of a Formal Group Program for Fatigue in Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
North Florida/South Georgia Veterans Health System, Gainesville, FL
mi
from
Gainesville, FL
A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis
A Randomized Trial of a Formal Group Program for Fatigue in Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
North Florida/South Georgia Veterans Health System, Gainesville, FL
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis
A Randomized Trial of a Formal Group Program for Fatigue in Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
VA Puget Sound Health Care System Seattle Division, Seattle, WA
mi
from
Seattle, WA
A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis
A Randomized Trial of a Formal Group Program for Fatigue in Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
VA Puget Sound Health Care System Seattle Division, Seattle, WA
mi
from
Seattle, WA
Click here to add this to my saved trials
A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis
A Randomized Trial of a Formal Group Program for Fatigue in Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis
A Randomized Trial of a Formal Group Program for Fatigue in Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Click here to add this to my saved trials
High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases
7T MRI Ferumoxytol-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases
Status: Enrolling
Updated:  12/31/1969
Richard M. Lucas Center for Imaging (of Stanford University)
mi
from
Stanford, CA
High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases
7T MRI Ferumoxytol-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases
Status: Enrolling
Updated: 12/31/1969
Richard M. Lucas Center for Imaging (of Stanford University)
mi
from
Stanford, CA
Click here to add this to my saved trials
High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases
7T MRI Ferumoxytol-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases
Status: Enrolling
Updated:  12/31/1969
Stanford Hospitals and Clinics
mi
from
Stanford, CA
High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases
7T MRI Ferumoxytol-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases
Status: Enrolling
Updated: 12/31/1969
Stanford Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis
Open-label, Single-blinded, Observational, Prospective, 24-months, Longitudinal, Controlled Study to Assess the Efficacy of Gilenya® on Development of Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
Buffalo Neuroimaging Analysis Center
mi
from
Buffalo, NY
Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis
Open-label, Single-blinded, Observational, Prospective, 24-months, Longitudinal, Controlled Study to Assess the Efficacy of Gilenya® on Development of Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
Buffalo Neuroimaging Analysis Center
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis
Autologous Adipose Stromal Vascular Fraction Outcomes Research Study
Status: Enrolling
Updated:  12/31/1969
StemGenex
mi
from
San Diego, CA
Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis
Autologous Adipose Stromal Vascular Fraction Outcomes Research Study
Status: Enrolling
Updated: 12/31/1969
StemGenex
mi
from
San Diego, CA
Click here to add this to my saved trials
Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.
Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.
Status: Enrolling
Updated:  12/31/1969
University of Southern California, Department of Neurology
mi
from
Los Angeles, CA
Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.
Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.
Status: Enrolling
Updated: 12/31/1969
University of Southern California, Department of Neurology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cullman, AL
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cullman, AL
Click here to add this to my saved trials
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials